HTSUY (Hisamitsu Pharmaceutical Co) Other Stockholders Equity: $356 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
67 GF Score
Price $2.94
GF Value $7.43
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co Other Stockholders Equity?

Hisamitsu Pharmaceutical Co HTSUY 67 Other Stockholders Equity is $356 Mil as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 67/100 and a GF Value™ of $7.43 (Significantly Undervalued).

Hisamitsu Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Nov. 2025 was $356 Mil.

Hisamitsu Pharmaceutical Co's quarterly Other Stockholders Equity declined from May. 2025 ($344 Mil) to Aug. 2025 ($329 Mil) but then increased from Aug. 2025 ($329 Mil) to Nov. 2025 ($356 Mil).

Hisamitsu Pharmaceutical Co's annual Other Stockholders Equity increased from Feb. 2024 ($324 Mil) to Feb. 2025 ($367 Mil) and increased from Feb. 2025 ($367 Mil) to Feb. 2026 ($448 Mil).

Hisamitsu Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Other Stockholders Equity Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.69 279.26 323.85 367.20 447.84

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 367.20 343.50 328.73 355.99 447.84
HTSUY
67GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $356 Mil mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a Other Stockholders Equity of $356 Mil as of Nov. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Other Stockholders Equity too high?
Hisamitsu Pharmaceutical Co's current Other Stockholders Equity is $356 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Other Stockholders Equity compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Other Stockholders Equity of $356 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Other Stockholders Equity is $356 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $7.43, compared to a current price of $2.94 — trading 60.4% below its estimated fair value. The current Other Stockholders Equity is $356 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current Other Stockholders Equity is $356 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued. The current stock price of $2.94 is trading 60.4% below its estimated GF Value™ of $7.43. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • Other Stockholders Equity: $356 Mil
  • GF Value™: $7.43 vs. price of $2.94 (60.4% below fair value)
  • GF Score™: 67/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
67GF Score

Get the complete analysis for HTSUY

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$7.43
GF Value